Towards more accurate HIV testing in sub-Saharan Africa: a multi-site evaluation of HIV RDTs and risk factors for false positives

Cara S Kosack1§, Anne-Laure Page2, Greet Beelaert3, Tumwesigye Benson4, Aboubacar Savane5, Anne Ng’ang’a6, Bita Andre7, Jean-Paul BN Zahinda8, Leslie Shanks1,9 and Katrien Fransen3

§Corresponding author: Cara S Kosack, Médecins sans Frontières, Plantage Middenlaan 14, 1018 DD Amsterdam, The Netherlands. (cara.kosack@amsterdam.msf.org)

Abstract
Introduction: Although individual HIV rapid diagnostic tests (RDTs) show good performance in evaluations conducted by WHO, reports from several African countries highlight potentially significant performance issues. Despite widespread use of RDTs for HIV diagnosis in resource-constrained settings, there has been no systematic, head-to-head evaluation of their accuracy with specimens from diverse settings across sub-Saharan Africa. We conducted a standardized, centralized evaluation of eight HIV RDTs and two simple confirmatory assays at a WHO collaborating centre for evaluation of HIV diagnostics using specimens from six sites in five sub-Saharan African countries.

Methods: Specimens were transported to the Institute of Tropical Medicine (ITM), Antwerp, Belgium for testing. The tests were evaluated by comparing their results to a state-of-the-art reference algorithm to estimate sensitivity, specificity and predictive values.

Results: 2785 samples collected from August 2011 to January 2015 were tested at ITM. All RDTs showed very high sensitivity, from 98.8% for First Response HIV Card Test 1–2.0 to 100% for Determine HIV 1/2, Genie Fast, SD Bioline HIV 1/2 3.0 and INSTI HIV-1/HIV-2 Antibody Test kit. Specificity ranged from 90.4% for First Response to 99.7% for HIV 1/2 STAT-PAK with wide variation based on the geographical origin of specimens. Multivariate analysis showed several factors were associated with false-positive results, including gender, provider-initiated testing and the geographical origin of specimens. For simple confirmatory assays, the total sensitivity and specificity was 100% and 98.8% for ImmunoComb II HIV 12 CombFirm (ImmunoComb) and 99.7% and 98.4% for Geenius HIV 1/2 with indeterminate rates of 8.9% and 9.4%.

Conclusions: In this first systematic head-to-head evaluation of the most widely used RDTs, individual RDTs performed more poorly than in the WHO evaluations: only one test met the recommended thresholds for RDTs of ≥99% sensitivity and ≥98% specificity. By performing all tests in a centralized setting, we show that these differences in performance cannot be attributed to study procedure, end-user variation, storage conditions, or other methodological factors. These results highlight the existence of geographical and population differences in individual HIV RDT performance and underscore the challenges of designing locally validated algorithms that meet the latest WHO-recommended thresholds.

Keywords: HIV; diagnostic; test; RDT; false positive

To access the supplementary material to this article please see Supplementary Files under Article Tools online.
The prevalence of HIV positives among the suspects tested at each study site was known. If it was ≥4%, we collected all specimens consecutively and calculated the total sample size based on the prevalence to obtain at least 200 HIV-positive and 200 HIV-negative samples and increased the calculated sample size by 10% to account for losses and/or problems in shipment.

If the prevalence of positive results was below 40%, we obtained a subsample of positive and negative specimens. Conservatively assuming 10% misclassification, we collected a sub-sample of 220 positive and 220 negative samples based on the on-site algorithm result. All samples with an inconclusive result were included. For this sampling strategy, we first included consecutively all clients, regardless of their results. Once the sample size for negative clients was reached, we stopped including HIV-negative clients (based on their on-site results) and included all clients diagnosed as HIV positive or inconclusive, for example, RDT1 positive and RDT2 negative, based on the on-site algorithm.

Study population
Clients ≥5 years of age who attended any of the participating HIV testing and counselling (HTC) centres and for whom written informed consent was provided by the client or legal guardian were included in the study. Upon enrolment, clients were offered HTC in accordance with site-specific procedures and testing algorithms. Exclusion criteria were: withdrawal of consent; inability to obtain a venous blood sample or insufficient blood; and current or past enrolment on anti-retroviral treatment.

Sample collection, storage and transportation
Venous EDTA blood was collected by the study nurse or laboratory technician. The EDTA blood samples were centrifuged, aliquoted and stored at −20 °C until being transported at 2–8 °C to the central laboratory (ITM) in Belgium. The storage temperature of freezers was monitored daily and a temperature recording system was used during transportation. At ITM, samples were immediately tested using the reference algorithm and remaining plasma samples were aliquoted further and stored a –20 °C until testing of RDTs.

Reference method for HIV diagnosis
Clients’ status was determined by using the reference standard algorithm at the AIDs reference laboratory at ITM, Antwerp, Belgium (Figure 1) on collected plasma samples. All samples were tested by a fourth generation ELISA (Vironostika® HIV Uni-Form II Ag/Ab, bioMérieux, France) and all reactive samples were confirmed by a Line-Immuannoassay (LIA, i.e. INNO-LIA™ HIV I/II Score, Innogenetics NV, Ghent, Belgium). Samples with a negative or indeterminate LIA were tested with an antigen-enzyme-immunoassay (Ag-EIA, i.e. INNOTEST HIV Antigen mAb, Innogenetics NV, Ghent, Belgium) to confirm acute infections. In the event that the LIA could not differentiate between HIV-1 and HIV-2, we used an in-house DNA PCR.
HIV RDT

The following eight HIV RDTs were tested at ITM on all plasma samples collected from the six study sites. Determine HIV-1/2 (Determine, Alere, USA; #7D2347), Uni-Gold HIV (Uni-Gold, Trinity Biotech, Ireland; #1206502), Genie Fast HIV 1/2 (Genie Fast, BioRad Laboratories, USA; #72330), Vikia HIV 1/2 (Vikia, bioMérieux, France; #31 112), HIV 1/2 STAT-PAK (STAT-PAK, Chembio, USA; #HIV101), INSTI HIV-1/HIV-2 Antibody Test (INSTIT, bioLytical, Canada; # 90–1021), SD Bioline HIV 1/2 3.0 (SD Bioline, Standard Diagnostics, Korea; #03FK10), and First Response HIV Card Test1–2.0 (First Response, PMC, India; # 05FRC30). Each test was read by two laboratory technicians who were blinded to each other’s result. If a reader disagreed, a third reader acted as tiebreaker.

All but one of the RDTs is prequalified by the WHO [21], and the one exception, Genie Fast, has been submitted for prequalification [22].

The two simple confirmatory assays evaluated were: ImmunoComb II HIV 1&2 CombFirm (ImmunoComb, Organics, Alere, Israel; #60434002) and Geenius HIV 1/2 confirmatory assay (Geenius, Bio-Rad, USA; #72460). The latter was interpreted both by using the Geenius reader system and the technician’s naked eye. Though neither of the simple confirmatory assays is WHO prequalified, the Geenius assay has been submitted for prequalification [22].

Tests were performed and interpreted according to the manufacturer’s instructions. An additional analysis was performed with the ImmunoComb using an alternate interpretation based on the strict criteria used in an earlier evaluation (Figure 2) [2].

All tests were read by two laboratory technicians who were blinded to each other’s interpretation and to the client’s HIV status. If the two readers disagreed, a third reader acted as tie-breaker. Band intensity was recorded by the two readers and graded from 1 to 3 (1 = weak line, 2 = medium strength line, 3 = strong line).

Statistical analysis

Data were analyzed using Stata version 13.1 (StataCorp, College Station, Texas, USA).

We estimated the sensitivity, specificity and predictive value for each RDT and simple confirmatory assay by comparing the results of these tests performed at ITM to the results of the reference standard. The analysis was weighted to adjust for the sampling strategy, which under-represented negative samples. For each participant, the weight was calculated as the inverse of the probability of inclusion in the study. For the total adjusted estimates, the weights were normalized to ensure equal representation of each site. Weighted proportions (e.g. weighted proportion of RDT reactive among all true positives by the reference standard for sensitivity) were calculated using the svy survey prefix command in Stata.

To measure inter-reader reliability, the level of concordance between results reported by the two laboratory...
technicians independently reading the test was evaluated using the kappa coefficient. A Kappa value ≥80% was considered very good agreement.

For each rapid test, factors associated with false positivity were analyzed using logistic regression with age, gender, inclusion site, entry mode and comorbidity included as covariates.

Ethics
The study was approved by the MSF Ethics Review Board and the Ethics Committee of the five countries where the study took place.

Results
Characteristics of the study population
From August 2011 to January 2015, a total of 2785 samples were collected at the six HTC sites and tested at the central laboratory (Table 1), with 437–500 samples collected per study site. Of the total 2785 samples, 1474 were found to be HIV negative and 1306 HIV positive (including one positive for HIV-2) by the reference algorithm (Figure 1). Three samples with indeterminate results and two classified as acute infections were excluded from the analysis.

Most study participants were females (61.9%). The median age of study participants was 30 (IQR: 24–39). Most participants presented for testing at the HTC facility voluntarily, or were referred by their spouse, with variations among sites (Table 1).

Diagnostic accuracy of the HIV RDTs
Adjusted (weighted) sensitivities ranged from 96.2% to 100% with specimens from different study sites (Table 2). Adjusted sensitivities <99% were found for four tests (Uni-Gold, Vikia, STAT-PAK and First Response) using specimens from Kitgum; and for the First Response test using specimens from Douala (97.7%) and Baraka (96.8%). The First Response was the only RDT with an overall (total) adjusted sensitivity <99% (Table 2). Unadjusted (unweighted/crude) sensitivities are shown in Additional File 1.

Adjusted specificities across the six sites varied from 77.0% for First Response on specimens from Kitgum to 100% for STAT-PAK on specimens from Conakry and Kitgum (Table 2). The INSTI and the First Response test had the lowest overall adjusted specificities (<90%), while STAT-PAK was the only RDT with an adjusted total specificity >98% (Table 2).

HIV RDTs differentiating HIV-1 and −2
Only the SD Bioline and First Response tests could distinguish HIV-1 and HIV-2 by a separate reaction line. Since only one participant was infected with HIV-2, we could not assess the tests’ sensitivity for HIV-2, only their specificity, which was 89.8% (95% CI: 88.6–90.9; 2490/2774) for SD Bioline and 96.1% (95% CI: 95.3–96.8; 2665/2774) for First Response (Table 3).

Band intensity and inter-reader agreement
The proportion of weak bands (intensity = 1) read by each of the readers is shown in Table 4. Weak bands were seen
Table 1. Demographic and clinical characteristics by study site

|                      | HTC, Conakry | Uganda, Kitgum | Uganda, Arua | Kenya, Homa Bay | Cameroun, Douala | DRC, Baraka | Total |
|----------------------|--------------|----------------|--------------|-----------------|-----------------|-------------|-------|
| Total tested at site |              |                |              |                 |                 |             |       |
| Total, n             | 793          | 1240           | 3159         | 2971            | 1003            | 1239        | 3610  | 14015 |
| Positive, n (%)      | 505 (63.7)   | 69 (5.5)       | 332 (10.5)   | 386 (13.0)      | 372 (37.1)      | 396 (32.0)  | 288 (8.0) | 2348 (16.8) |
| Negative, n (%)      | 278 (35.0)   | 1169 (94.3)    | 2827 (89.5)  | 2585 (87.0)     | 617 (61.5)      | 826 (66.7)  | 3252 (90.1) | 11554 (82.4) |
| Indeterminates, n (%)| 10 (1.3)     | 2 (0.2)        | 0 (0)        | 14 (1.4)        | 17 (1.4)        | 70 (1.9)    | 113 (0.8)  |       |
| Included in the study based on HIV status tested at site |              |                |              |                 |                 |             |       |
| Total, n             | 341          | 105            | 437          | 443             | 500             | 462         | 497   | 2785  |
| Positive, n (%)      | 220 (64.5)   | 2 (1.9)        | 217 (49.7)   | 212 (47.9)      | 223 (44.6)      | 222 (48.1)  | 221 (44.5) | 1317 (47.3) |
| Negative, n (%)      | 117 (34.3)   | 103 (98.1)     | 220 (50.3)   | 231 (52.1)      | 277 (55.4)      | 230 (49.8)  | 220 (44.2) | 1398 (50.2) |
| Indeterminates, n (%)| 4 (1.2)      | 0 (0)          | 0 (0)        | 0 (0)           | 10 (2.2)        | 56 (11.3)   | 70 (2.5)  |       |
| Entry mode           |              |                |              |                 |                 |             |       |
| Voluntary testing, n (%) | 0 (0)     | 323 (73.9)    | 443 (100)    | 459 (91.8)      | 211 (45.7)      | 187 (37.8)  | 1623  |       |
| Spouse               | 238 (53.4)   | 20 (4.6)       | 0 (0)        | 0 (0)           | 251 (54.3)      | 10 (2.0)    | 519   |       |
| Referred – TB clinic, n (%) | 57 (12.8)  | 2 (0.5)        | 0 (0)        | 21 (4.2)        | 0 (0)           | 3 (0.6)     | 83    |       |
| Referred – IPD, n (%) | 33 (7.4)     | 0 (0)          | 0 (0)        | 0 (0)           | 297 (59.8)      | 330         |       |       |
| Referred – OPD, n (%) | 13 (2.9)     | 33 (7.5)       | 0 (0)        | 0 (0)           | 0 (0)           | 46          |       |       |
| ANC, n (%)           | 105 (23.3)   | 54 (12.4)      | 0 (0)        | 20 (4.0)        | 0 (0)           | 0 (0)       | 179   |       |
| Other, n (%)         | 0 (0)        | 5 (1.1)        | 0 (0)        | 0 (0)           | 0 (0)           | 0 (0)       | 5     |       |
| Age and gender       |              |                |              |                 |                 |             |       |
| Median age (IQR)     | 29 (22–39)   | 30 (24–39)     | 29 (23–37)   | 30 (23–40)      | 31 (25–41)      | 30 (23–39)  | 30 (24–39) |       |
| Males, n (%)         | 132 (29.6)   | 176 (40.3)     | 213 (48.2)   | 201 (40.2)      | 163 (35.3)      | 177 (35.6)  | 1062 (38.1) |       |

HTC = HIV testing and counselling, ANC = antenatal care, TB = tuberculosis, IPD = in-patient department; OPD = out-patient department.
| Table 2. Weighted diagnostic accuracy of HIV RDTs |
|------------------------------------------------|
| **Kosack CS et al.** | **Sensitivity; 95% CI** |
| Guinea, Conakry | 100; 98.3–100 |
| Uganda, Kitgum | 100; 98.3–100 |
| Uganda, Arua | 100; 98.3–100 |
| Kenya, Homa Bay | 100; 98.3–100 |
| Cameroun, Douala | 100; 98.3–100 |
| DRC, Baraka | 100; 98.3–100 |
| **Total** | 100; 98.3–100 |

**Specificity; 95% CI**

| **Determine** | 100; 98.3–100 |
| **Uni-Gold** | 100; 98.3–100 |
| **Genie Fast** | 100; 98.3–100 |
| **Vikia** | 100; 98.3–100 |
| **STAT-PAK** | 100; 98.3–100 |
| **INSTI** | 100; 98.3–100 |
| **SD Bioline** | 100; 98.3–100 |
| **First Response** | 100; 98.3–100 |

**Positive predictive value; 95% CI**

| **Determine** | 99.0; 97.7–99.6 |
| **Uni-Gold** | 99.2; 94.7–99.9 |
| **Genie Fast** | 97.5; 93.9–99.0 |
| **Vikia** | 99.0; 97.7–99.6 |
| **STAT-PAK** | 98.0; 94.1–99.3 |
| **INSTI** | 99.7; 98.7–99.9 |
| **SD Bioline** | 98.0; 94.1–99.3 |
| **First Response** | 99.7; 98.7–99.9 |

**Negative predictive value; 95% CI**

| **Determine** | 100; 98.3–100 |
| **Uni-Gold** | 100; 98.3–100 |
| **Genie Fast** | 100; 98.3–100 |
| **Vikia** | 100; 98.3–100 |
| **STAT-PAK** | 100; 98.3–100 |
| **INSTI** | 100; 98.3–100 |
| **SD Bioline** | 100; 98.3–100 |
| **First Response** | 100; 98.3–100 |
only with the SD Bioline and First Response tests and represented up to half of the total reactive HIV-2 lines (Tables 3 and 4).

Table 3. Comparison of SD Bioline HIV 1/2 3.0 and first response HIV Card Test 1-2.0 with the reference method results, including differentiation between HIV-1 and HIV-2 (N = 2780)

| Results of the reference test | Negative | HIV-1 | HIV-2 | HIV* | Total |
|------------------------------|----------|-------|-------|------|-------|
| SD Bioline                   |          |       |       |      |       |
| Non-reactive                 | 1431     | 1     | 0     | 0    | 1432  |
| HIV-1                        | 31       | 1027  | 0     | 1    | 1059  |
| HIV-2                        | 10       | 4     | 1     | 0    | 15    |
| HIV-1 & HIV-2                | 2        | 268   | 0     | 4    | 274   |
| First Response               |          |       |       |      |       |
| Non-reactive                 | 1332     | 15    | 0     | 0    | 1347  |
| HIV-1                        | 119      | 1199  | 0     | 2    | 1320  |
| HIV-2                        | 1        | 0     | 1     | 0    | 2     |
| HIV-1 & HIV-2                | 22       | 86    | 0     | 3    | 111   |
| Total                        | 1474     | 1300  | 1     | 5    | 2780  |

*Specimens could not be differentiated because the dried blood spot sample for PCR was not collected.

Table 4. Proportion of weak bands (line intensity = 1) per RDT (N = 2780)

| Reader A | Reader B |
|----------|----------|
| n        | Proportion (%) | Proportion (%) |
|          | overall | positives | overall | positives |
| Determine | 0       | 0         | 0       | 0         |
| Uni-Gold  | 0       | 0         | 1       | 0         |
| Genie Fast| 0       | 0         | 0       | 0         |
| Vikia     | 0       | 0         | 0       | 0         |
| STAT-PAK  | 0       | 0         | 0       | 0         |
| INSTI     | 0       | 0         | 0       | 0         |
| SD Bioline – line 1 | 29 | 1.0 | 2.2 | 29 | 1.0 | 2.2 |
| SD Bioline – line 2 | 265 | 9.5 | 46.7 | 268 | 9.6 | 47.8 |
| First Response – line 1 | 262 | 9.4 | 18.2 | 237 | 8.5 | 16.5 |
| First Response – line 2 | 66 | 2.4 | 51.2 | 54 | 1.9 | 42.5 |

Diagnostic accuracy of the simple HIV confirmatory assays

The total adjusted sensitivity of both simple confirmatory assays was close to 100% (Table 6). The specificity of the ImmunoComb increased from 98.9% seen with the manufacturer’s recommended interpretation to 99.4% when using the alternative interpretation criteria [18], while the rate of indeterminate results increased from 8.9% to 9.8.

The specificity of the Geenius assay varied from 97.6% to 98.3% for visual versus automated reading with similar rates of indeterminate results for visual reading (9.2%) and automated reading (9.4%). Overall, measurement with the automated reader was as accurate or more than with the naked eye (Table 6).

Similar to results for the RDTs, specificities of both simple confirmatory assays varied across sites, with the lowest specificities recorded on specimens from Baraka (Table 6). Unadjusted (unweighted/crude) performance data are displayed in Additional File 2.

False reactive results and their associated risk factors

A total of 438 specimens gave false-positive results with at least one RDT. False-positive results were associated with different factors for each of the tests, as shown by the odds ratio for false-positive results in a multivariate analysis.
Table 5. Inter-reader agreement (kappa) and absolute number of disagreements for all RDTs and simple confirmatory assays (n = 2785)

| RDT/Assay                  | Number of disagreements | Kappa |
|----------------------------|-------------------------|-------|
| Determine                  | 8                       | 99.4  |
| Uni-Gold                   | 2                       | 99.9  |
| Genie Fast                 | 5                       | 99.6  |
| Vikia                      | 0                       | 100.0 |
| STAT-PAK                   | 0                       | 100.0 |
| INSTI                      | 14                      | 99.0  |
| SD Bioline                 | 5                       | 99.6  |
| First Response             | 28                      | 98.0  |
| ImmunoComb II HIV 1&2      | 51                      | 95.2  |
| CombFirm                   |                         |       |
| gp24                       | 25                      | 99.1  |
| gp31                       | 58                      | 97.9  |
| gp120                      | 16                      | 99.4  |
| gp41                       | 6                       | 99.8  |
| gp36                       | 12                      | 99.6  |
| Geenius HIV 1/2 confirmatory assay | 85 | 96.9 |
| gp36                       | 8                       | 99.7  |
| gp140                      | 83                      | 97.0  |
| gp31                       | 73                      | 97.4  |
| gp160                      | 5                       | 99.8  |
| gp24                       | 67                      | 97.7  |
| gp41                       | 18                      | 99.4  |

(Table 7). For Determine, the main determinant for a false-positive result was to be referred for testing by a clinician from the IPD, OPD or the TB clinic (i.e. possibly due to presence of comorbidities), whereas with Genie Fast and Vikia, a false positive was mostly strongly associated with being male. Differences by origin remained significant only for INSTI, SD Bioline, and First Response. More detailed analyses per test are provided in Additional File 3.

Discussion

Growing awareness of problems with patient misdiagnosis at some HIV testing sites in sub-Saharan Africa, and inconsistent findings on the accuracy of widely used simple diagnostic tests, have highlighted the urgent need for a comprehensive, systematic evaluation of these tests, with special emphasis variation in their performance by geographical location and other characteristics [5]. All but one of the RDTs evaluated here has been WHO prequalified, and of them, only STAT-PAK recorded a final sensitivity of less than 100% (99.5%) [6,7]. The final specificities in the WHO prequalification evaluations were: 100% for STAT-PAK, 99.9% for SD Bioline and Vikia, 99.4% for First Response and 98.9% for Determine [6,7]. However, in our evaluation, individual RDTs performed more poorly than in WHO evaluations with only one test (STAT-PAK) meeting the recommended thresholds for RDTs of ≥99% sensitivity and ≥98% specificity when using total estimates [1]. None of the tests met the WHO-recommended thresholds for sensitivity and specificity when using the lower end of the 95% CI [1].

While all but one HIV RDT and two simple confirmatory assays had total adjusted sensitivities ≥99%, the biggest problem identified was specificity, which varied widely among the different tests and by samples’ origin. Only one of the eight tests (STAT-PAK) had a total adjusted specificity ≥98%, exceeding the WHO-recommended threshold (lower end of the 95% CI of ≥98%) [1] at five of six sites; two other tests (SD Bioline and First Response) exceeded it at one site. Although confirmatory assays are presumed to have higher specificity than RDTs, the two simple confirmatory assays evaluated here showed a specificity ≥98% at only half the study sites. None of the confirmatory assay met the WHO threshold of the lower end of the 95% CI interval of ≥99% [1].

It has been proposed that cross reactivity, either direct or indirect, may be responsible for the variable performance of RDTs in different populations and test sites, and that comorbid disease, such as kala azar, sleeping sickness and schistosomiasis, could play a role [23–26]. Polyclonal B cell activation to various infections could account for the heterogeneity in test performance across different populations [27]. In our study, co-morbidities were assessed only by self-reporting, and no significant association with false reactive results could be established.

Interestingly, being referred by a clinician from the IPD, OPD or TB clinic (as a result having one or more co-morbidities) was a risk factor for false reactivity, but only for Determine. In contrast, for Genie Fast and Vikia, the main risk factor associated with false reactive results was male gender with a 2–3-fold increased risk. Finally, the origin of the participants was highly associated with false reactivity on the INSTI, SD Bioline and First Response tests, indicating the presence of unknown site-specific factors.

It has been postulated that weak reactive test lines/dots are more likely to be false positive than true positive results and that considering them as potentially negative might reduce false-positive results [2,10,15,18,19,28,29]. We detected weak testing lines only with SD Bioline and First Response, the latter showing weak results on almost 50% of reactive tests for HIV-2. For other tests, however, no weak lines were reported, meaning that even false reactive/positive results produced a line of at least medium intensity. This presumably helped reduce variability between test readers: inter-reader agreement was very high (kappa coefficients ≥0.98) for all tests, in line with WHO recommendations of an inter-reader variability <5% [1].

Specificity for HIV-2 for the SD Bioline and First Response tests was low: 89.8% and 96.1% respectively. This confirms results of the WHO prequalification evaluations, which found that RDTs showed a wide range of cross-reactivity (3–57%) on the HIV-2 line, potentially leading to significant false diagnosis of HIV-2 infections. However, as the concerned RDTs are WHO prequalified, providers and patients may be lead to believe...
Table 6. Weighted/adjusted diagnostic accuracy of two simple confirmatory assays

| ImmunoComb II HIV 1&2 CombFirm – interpretation according to manufacturer | Guinea, Conakry | Uganda, Kitgum | Uganda, Arua | Kenya, Homa Bay | Cameroun, Douala | DRC, Baraka | Total |
|---|---|---|---|---|---|---|---|
| Sensitivity; 95% CI | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 99.7–100 |
| Specificity; 95% CI | 99.7; 98.6–99.9 | 98.3; 94.9–99.5 | 97.7; 94.1–99.1 | 100; 98.4–100 | 99.1; 96.6–99.7 | 98.5; 95.8–99.5 | 98.8; 98.0–99.3 |
| PPV; 95% CI | 99.2; 96.7–99.8 | 89.4; 72.8–96.4 | 90.1; 77.6–96.0 | 100; 98.4–100 | 98.2; 94.1–99.5 | 88.3; 71.5–95.7 | 96.5; 94.3–97.9 |
| NPV; 95% CI | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.2–100 | 100; 99.7–100 |

| ImmunoComb II HIV 1&2 CombFirm – alternative interpretation | Guinea, Conakry | Uganda, Kitgum | Uganda, Arua | Kenya, Homa Bay | Cameroun, Douala | DRC, Baraka | Total |
|---|---|---|---|---|---|---|---|
| Sensitivity; 95% CI | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 99.7–100 |
| Specificity; 95% CI | 99.7; 98.6–99.9 | 98.3; 94.9–99.5 | 99.3; 96.4–99.9 | 100; 98.4–100 | 99.9; 97.7–99.9 | 99.9; 99.7–100 | 99.5; 98.9–99.8 |
| PPV; 95% CI | 99.2; 96.7–99.8 | 89.2; 72.5–96.3 | 97.0; 85.1–99.5 | 100; 98.4–100 | 99.6; 97.0–100 | 98.5; 96.7–99.4 | 100; 99.7–100 |
| NPV; 95% CI | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.2–100 | 100; 99.7–100 |

| Geenius HIV 1/2 confirmatory assay – automated reading | Guinea, Conakry | Uganda, Kitgum | Uganda, Arua | Kenya, Homa Bay | Cameroun, Douala | DRC, Baraka | Total |
|---|---|---|---|---|---|---|---|
| Sensitivity; 95% CI | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 99.7–100 |
| Specificity; 95% CI | 98.4; 95.0–99.5 | 98.3; 94.8–99.5 | 97.0; 93.0–98.7 | 100; 98.4–100 | 98.9; 96.9–99.6 | 98.4; 95.8–99.4 | 98.4; 97.5–99.0 |
| PPV; 95% CI | 96.5; 89.4–98.9 | 89.4; 72.8–96.4 | 88.0; 75.4–94.6 | 100; 98.4–100 | 97.7; 93.7–99.2 | 86.9; 71.5–94.6 | 95.5; 93.0–97.1 |
| NPV; 95% CI | 100; 98.1–100 | 100; 98.3–100 | 100; 98.7–100 | 100; 98.4–100 | 100; 98.4–100 | 100; 98.2–100 | 100; 99.9–100 |

| Geenius HIV 1/2 confirmatory assay – visual reading | Guinea, Conakry | Uganda, Kitgum | Uganda, Arua | Kenya, Homa Bay | Cameroun, Douala | DRC, Baraka | Total |
|---|---|---|---|---|---|---|---|
| Sensitivity; 95% CI | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 98.3–100 | 100; 99.7–100 |
| Specificity; 95% CI | 98.2; 95.0–99.4 | 97.8; 94.2–99.2 | 94.7; 90.2–97.2 | 100; 98.4–100 | 98.9; 96.8–99.6 | 98.3; 95.7–99.4 | 97.9; 96.9–98.6 |
| PPV; 95% CI | 96.1; 89.3–98.6 | 86.3; 70.0–94.5 | 80.4; 67.9–88.9 | 100; 98.4–100 | 97.7; 93.7–99.2 | 86.9; 71.4–94.6 | 94.1; 91.4–96.0 |
| NPV; 95% CI | 100; 98.1–100 | 100; 98.3–100 | 100; 98.4–100 | 100; 98.4–100 | 100; 98.4–100 | 100; 98.1–100 | 100; 99.9–100 |

PPV = positive predictive value, NPV = negative predictive value.
Table 7. Odds ratio for false-positive results in a multivariate analysis for each rapid test.

| Gender | Determine | Uni-Gold | Genie Fast | Vikia | INSTI | SD Bioline | First Response |
|--------|-----------|----------|------------|-------|-------|------------|----------------|
| Female | Ref       | Ref      | Ref        | Ref   | Ref   | Ref        | Ref            |
| Male   | 1.77 (0.21–2.6) | 1.57 (0.80–3.1) | **2.94 (1.90–4.6)** | **2.09 (1.22–3.6)** | **1.68 (1.17–2.4)** | 0.68 (0.35–1.3) | 0.88 (0.60–1.3) |
| Age group | <15 | Ref | Ref | Ref | Ref | Ref | Ref |
| 15–29 | 0.80 (0.29–2.2) | 1.16 (0.15–9.2) | 1.23 (0.35–4.3) | 3.22 (0.41–25.6) | 0.83 (0.30–2.3) | 0.65 (0.14–3.0) | 2.28 (0.52–9.9) |
| 30–44 | 0.74 (0.27–2.1) | 0.67 (0.08–5.8) | 1.08 (0.30–3.9) | 2.76 (0.34–22.2) | 0.68 (0.24–1.9) | 1.09 (0.23–5.0) | 2.21 (0.50–9.8) |
| 45–60 | 1.11 (0.37–3.3) | 1.77 (0.20–15.9) | 1.27 (0.32–4.9) | 4.75 (0.57–39.5) | 0.93 (0.30–2.8) | 0.35 (0.05–2.6) | 3.08 (0.66–14.3) |
| >60   | 1.78 (0.51–6.3) | 4.11 (0.41–41.1) | 2.33 (0.51–10.8) | 8.37 (0.88–80.0) | 1.75 (0.49–6.2) | 1.27 (0.16–9.9) | 1.97 (0.33–11.9) |
| Site  | Conakry | Ref | Ref | Ref | Ref | Ref | Ref |
| Kitgum | 1.65 (0.82–3.3) | 0.93 (0.03–24.7) | 1.40 (0.37–5.3) | 1.65 (0.25–10.9) | 2.07 (0.52–8.2) | 3.55 (0.39–32.3) | **4.20 (1.24–14.2)** |
| Arua  | 0.29 (0.07–1.2) | 1.45 (0.05–39.3) | 2.68 (0.68–10.5) | 2.18 (0.32–14.8) | **7.42 (1.86–29.6)** | **9.83 (1.06–91.4)** | **11.94 (3.47–41.1)** |
| Homa Bay | 1.14 (0.56–2.3) | 0.45 (0.02–12.9) | 0.69 (0.17–2.8) | 1.55 (0.24–10.0) | 2.06 (0.52–8.2) | 6.74 (0.79–57.8) | **6.59 (2.00–21.7)** |
| Baraka | 0.69 (0.33–1.4) | 2.58 (0.10–66.1) | 1.76 (0.47–6.7) | 3.08 (0.51–18.5) | **17.6 (4.7–66.5)** | **10.70 (1.18–96.9)** | 3.33 (0.91–12.1) |
| Douala | 1.14 (0.55–2.3) | 1.10 (0.04–29.0) | 0.91 (0.23–3.7) | 1.51 (0.23–9.8) | **9.9 (2.6–38.4)** | 2.16 (0.19–24.3) | 0.17 (0.02–1.75) |
| Entry mode | Voluntary | Ref | Ref | Ref | Ref | Ref | Ref |
| Spouse | 0.68 (0.15–3.0) | N/A | 0.70 (0.15–3.3) | 2.06 (0.39–10.8) | 1.07 (0.25–4.6) | 1.74 (0.24–12.5) | 0.29 (0.03–2.4) |
| Referred* | **1.79 (1.07–3.0)** | 1.46 (0.63–3.4) | 1.43 (0.76–2.7) | 1.48 (0.70–3.2) | 1.23 (0.79–1.9) | 1.30 (0.50–3.4) | 0.76 (0.34–1.7) |
| ANC  | 0.50 (0.11–2.3) | 0.46 (0.02–11.3) | 0.81 (0.21–3.1) | N/A | 2.14 (0.63–7.3) | 1.50 (0.26–8.6) | 1.28 (0.52–3.1) |
| Comorbidity | Malaria | 2.62 (1.21–5.6) | 1.81 (0.39–8.3) | 1.19 (0.42–3.3) | 1.86 (0.60–5.7) | 1.00 (0.38–2.6) | 1.86 (0.54–6.4) | 0.97 (0.41–2.3) |
| TB    | 1.08 (0.36–3.3) | N/A | 0.54 (0.13–2.3) | 0.69 (0.13–3.8) | 0.84 (0.26–2.7) | N/A | 1.35 (0.34–5.4) |

Significant results are highlighted in bold.
N/A = not applicable.
STAT-PAK was excluded because too few false-positive results were obtained.
*Referred by a clinician from the in-patient department, the out-patient department or the TB clinic.
that they are double-infected or solely infected with HIV-2, a less aggressive form of the virus [7].

Several possible limitations related to the use of RDTs in this study should be noted. First, RDTs are designed for use on fresh specimens; in practice this usually means capillary whole blood. As it happened, this study used plasma samples that had been frozen, shipped, and stored before testing. Some studies have shown differences in sensitivity and specificity when using plasma/serum compared to capillary whole blood [13,28,30]. Second, our evaluation was carried out on one batch of index tests, precluding a comparison between batches. Third, considering the relatively low prevalence of HIV in some testing sites, we decided not to include all consecutive clients but, instead, all consecutive positives and a fixed number of negative clients. In doing so, we introduced verification bias, resulting in a sample that was not representative of the overall population. We therefore performed a weighted analysis to account for the sampling strategy, and acknowledge that these estimates are not as solid as they would be had we carried out consecutive sampling. Last but not least, the simple confirmatory assays need to be evaluated in as part of an algorithm in addition to individual performance.

Conclusions

In summary, the findings of this large multi-centre study indicate that HIV RDT performance can vary greatly according to patient’s gender, comorbidities, and other unknown factors associated to geographical location, even within in a single country. By performing all tests in a centralized setting, we show that these differences in performance cannot be attributed to study procedure, end-user variation or storage conditions. Also, simple confirmatory assays in this study had imperfect and varying specificities according to origin of specimens, suggesting that they may not provide an appropriate universal solution in all geographical locations to the problem of false-positive results. Finally, these results underscore the need for local validation of HIV RDTs in order to design accurate testing algorithms.

Authors’ affiliations

1 Médecins sans Frontières, Diagnostic Network, Amsterdam, Netherlands; 2 Epincentre, Epidemiology and Population Health Department, Paris, France; 3 Institute of Tropical Medicine, AIDS Reference Laboratory, Antwerp, Belgium; 4 Ministry of Health Uganda, STO/AIDS Control Program, Kampala, Uganda; 5 Ministry of Health Guinea, Laboratoire National de Reference, Conakry, Guinea; 6 Ministry of Health Kenya, National AIDS and Sexually Transmitted Infections Control Programme, Nairobi, Kenya; 7 Ministry of Health Cameroon, Regional Delegation of Public Health for the Littoral Region, Yaounde, Cameroon; 8 Ministry of Health Democratic Republic of Congo, Programme National de Lutte contre le Sida et les IST (PNLS), Bukavu, Democratic Republic of Congo; 9 Public Health Department, Médecins sans Frontières, Amsterdam, Netherlands

Competing interests

All authors declare no competing interests.

Authors’ contributions

C.S. Kosack, A-L. Page, L. Shanks and K. Fransen designed the study and wrote the study protocol. C.S. Kosack, A-L. Page, T. Benson, A. Savane, A. Ng'ang’a, B. Andre and J-P. B. N. Zahinda and G. Beelaert contributed to the study implementation at the different sites. G. Beelaert and K. Fransen performed the laboratory analysis and data collection at the reference laboratory. C.S. Kosack, A-L. Page, L. Shanks and K. Fransen prepared the manuscript. T. Benson, A. Savane, A. Ng’ang’a, B. Andre and J-P. B. N. Zahinda and G. Beelaert contributed to the data interpretation and reviewed the manuscript. All authors have read and approved the final version.

Acknowledgements

We acknowledge to all study participants. We acknowledge the assistance of health facility staff and the counsellors at each site. We are grateful to the MSF’s laboratory working group members for the invaluable support during the entire planning and rollout of the study: Erwan Piriou, Charity Kamau, Pamela Hepple, Pascale Chaillot, Monique Gueguen, Celine Lastrucci, Laurence Bonte, and Roberto de la Tour. We also thank Meggy Verputten, Karla Bil, Annick Antierens, and Suna Balkan at MSF headquarters for supporting the study. We thank Patricia Kahn and Patrick Adams for the editing comments. We also thank the MSF and the local ethical review boards for the critical review and feedback of the study protocol.

Especially we thank the following study team members and local supporters of the study: J Mashala, H Onyango, E Ouyo, E Abich, S Oiyugi, J Animo, C Mugo, N Jaleny, F Duvall, S Matiku, P Balkagia, Z Tu, H Elyas, S Adega, and B Kirubi (Noma-Bay, Kenya); S Noubiissi, I Essomba, P Ndbo, C Tchimou, and G Ehounou (Douala, Cameroon), J Wazome, H Nordenstedt, P Kahindo, J Maphenzndaheli, A Uunda, N Amwabo, L Byantuku, P Tawimb, M Diao, and E Castagna (Baraka, DRC); C Gba-Foromo (Conakry, Guinea); P Ongeyowon, M Baral-Baron, K Kelly, C Paye, K Chipemba, J Sande, I Quiles, and V de Clerck (Arush, Uganda); R Aupai, R Olal, Shoab, Y Boum and S Muhammad (Kitgum, Uganda).

This work was supported by the Innovation Fund of Médecins sans Frontières (Grant number: OR 08 02). MSF’s Innovation Fund provided funding for sample collection at the study sites, shipment to the central laboratory, and analysis at the ITM central laboratory. The study sponsor had no role in the study design, data collection, analysis and interpretation of the data or in the decision to submit for publication. The corresponding author had access to all data and final responsibility for the decision to submit for publication.

References

[1] World Health Organization. WHO consolidated guidelines on HIV testing services. Geneva, Switzerland: World Health Organization; 2015 Jul [cited 2016 Dec 20]. Available from: http://apps.who.int/iris/bitstream/10665/179870/1/9789241508916_eng.pdf?ua=1
[2] Klarkowski DB, Wazome JM, Lokoje KM, Shanks L, Mills CF, O’Brien DP. The evaluation of a rapid in situ HIV confirmation test in a programme with a high failure rate of the WHO HIV two-test diagnostic algorithm. PLoS One. 2009 2;4:e4351.
[3] Shanks L, Siddiqui MR, Kleissokova J, Pearce N, Ariri C, Mulene L, et al. Evaluation of HIV testing algorithms in Ethiopia: the role of the tie-breaker algorithm and weakly reacting test lines in contributing to a high rate of false positive HIV diagnoses. BMC Infect Dis. 2015;15:39.
[4] Shanks L, Klarkowski D, O’Brien DP. False positive HIV diagnoses in resource limited settings: operational lessons learned for HIV programmes. PLoS One. 2013;8:8–13.
[5] World Health Organization. ANNEX 14. A report on the misdiagnosis of HIV status in: WHO consolidated guidelines on HIV testing services. Geneva, Switzerland: World Health Organization; 2015 Jul [cited 2016 Dec 20]. Available from: http://apps.who.int/iris/bitstream/10665/180231/1/WHO_HIV_2015.33_eng.pdf
[6] World Health Organization. HIV assays: operational characteristics. HIV rapid diagnostic tests (detection of HIV-1/2 antibodies). Report 17. Geneva, Switzerland: World Health Organization; 2013 [cited 2016 Dec 20]. Available from: http://www.who.int/diagnostics_laboratory/evaluations/hiv/113107_hiv_ assays17_final.pdf
[7] World Health Organization. HIV assays. Laboratory performance and other operational characteristics. Rapid diagnostic tests. Report 18. Geneva, Switzerland: World Health Organization; 2015 [cited 2016 Dec 20].
Kosack CS et al. Journal of the International AIDS Society 2017, 20:21345
http://www.jiasociety.org/index.php/jias/article/view/21345 | http://dx.doi.org/10.7448/IAS.20.1.21345

Available from: http://www.who.int/diagnostics_laboratory/publications/15032_hiv_assay_report18.pdf

[8] Juarez SI, Nuñez AE, Aranda MM, Mojica D, Kim A, Parekh B. Field evaluation of 4 rapid tests for diagnosis of HIV infection in Panama. J Clin Microbiol. 2016 Apr;54(4):1127–29.

[9] Pai NP, Balram B, Shvikumar S, Martínez-Cajas JL, Classens C, Lambert G, et al. Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:373–80.

[10] Kagulire SC, Opendi P, Stampler PD, Nakavuma JL, Mills LA, Makumbi F, et al. Field evaluation of five rapid diagnostic tests for screening of HIV-1 infections in rural Rakai, Uganda. Int J STD AIDS. 2011;22:308–09.

[11] Zeh C, Oyaro B, Vandenhoudt H, Amornkul P, Kasembeli A, Bondo P, et al. Performance of six commercial enzyme immunoassays and two alternative HIV-testing algorithms for the diagnosis of HIV-1 infection in Kisumu, Western Kenya. J Virol Methods. 2011;176:24–31.

[12] Delaney KP, Branson BM, Uniyal A, Phillips S, Candal D, Owen SM, et al. Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clin Infect Dis. 2011 Jan 15;52(2):257–63.

[13] Pavli J, Rachline A, Loze B, Niedbalski I, Delaugerre C, Laforgerie E, et al. Sensitivity of five rapid HIV tests on oral fluid or Finger-Stick whole blood: a real-time comparison in a healthcare setting. PLoS One. 2010 Jul 19;5(7):e11581.

[14] Aghokeng AF, Mpoudi-Ngole E, Dimodi H, Atem-Tambe A, Tongo M, Butel C, et al. Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon. PLoS One. 2009 Nov 6;4(11):e7702.

[15] Anzala O, Sanders EJ, Kamali A, Katende M, Mutua GN, Ruzagira E, et al. Sensitivity and specificity of HIV rapid tests used for research and voluntary counselling and testing programmes in East Africa. East Afr Med J. 2008;85:500–4.

[16] Singer DE, Kiwanuka N, Lutalo T, Makumbi F, Panse L, Opendi P, et al. Accounting for false positive HIV tests: is visceral leishmaniasis responsible? PLoS One. 2010;5:80.

[17] Shanks L, Rimes D, Pirou E, Siddiqui MR, Kliescikova J, Pearse N, et al. Association of schistosomiasis with false-positive HIV test results in an African adolescent population. J Clin Microbiol. 2010 May;48(5):1570–77.

[18] Everett DB, Bassely KJ, McNerney R, Hambleton I, Chirwa T, Ross DA, et al. Association of schistosomiasis with false-positive HIV test results in an African adolescent population. J Clin Microbiol. 2010 May;48(5):1570–77.

[19] Gray RH, Makumbi F, Serwadda D, Lutalo T, Nakagudha F, Opendi P, et al. Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study. Bmj. 2007;335:188.

[20] CDC, WHO/AFRO, APHL. Guidelines for appropriate evaluations of HIV testing technologies in Africa. 2002. p. 1–46. [cited 2016 Dec 20]. Available from: http://www.who.int/epidemiology/161205_prequalified_product_list.pdf

[21] World Health Organization. 2016. WHO list of prequalified in vitro diagnostic products. Geneva, Switzerland: World Health Organization. [updated 2016 Dec 5; cited 2016 Dec 20]. Available from: http://www.who.int/diagnostics_laboratory/evaluations/161205_prequalified_product_list.pdf

[22] World Health Organization. 2016. HIV rapid tests: progress of the active applications in the prequalification of IVDs assessment pipeline. Geneva, Switzerland: World Health Organization. [updated 2016 Oct 3; cited 2016 Dec 20]. Available from: http://www.who.int/diagnostics_laboratory/161003_hiv_rapid.pdf

[23] Shanks L, Rimes D, Pirou E, Siddiqui MR, Kliescikova J, Pearse N, et al. Accounting for false positive HIV tests: is visceral leishmaniasis responsible? PLoS One. 2010;5:80.

[24] Lejon V, Mumba Ngoyi D, Hunga M, Beelaert G, Maes I, Büscher P, et al. Low specificities of HIV diagnostic tests caused by trypanosomiasis brucei gambiense sleeping sickness. J Clin Microbiol. 2010;48:2836–39.

[25] Everett DB, Bassely KJ, McNerney R, Hambleton I, Chirwa T, Ross DA, et al. Association of schistosomiasis with false-positive HIV test results in an African adolescent population. J Clin Microbiol. 2010 May;48(5):1570–77.

[26] Riberio TT, Brites C, Moreira ED Jr, Siller K, N, Johnson WD Jr, et al. Serologic validation of HIV infection in a tropical area. J Acquir Immune Defic Syndr. 1993 Mar;6(3):219–22.

[27] Klarkowski D, Brien D, Shanks L, Singh KP. Causes of false positive HIV rapid diagnostic test results. Expert Rev Anti Infect Ther. 2014 Jan;12(1):49–62.

[28] Kroidl I, Clowes P, Mwalongo W, Maganga L, Maboko L, Kroidl AL, et al. Low specificity of determine HIV 1/2 antibody tests: is there a difference between the visual appearance of true- and false-positive test results? Int J STD AIDS. 2012 Sep;23(9):644–52.

[29] Sacks R, Omodele-Lucien A, Whitbread N, Muir D, Smith A. Rapid HIV testing using Determine™ HIV 1/2 antibody tests: is there a difference between the visual appearance of true- and false-positive test results? Int J STD AIDS. 2012 Sep;23(9):644–52.

[30] Boadu R, Darko G, Nortey P, Akwengha P, Sarfo B. Assessing the sensitivity and specificity of first response HIV-1/2 test kit with whole blood and serum samples: a cross-sectional study. AIDS Res Ther. 2016 Feb 16; 13:9. eCollection 2016.

[31] Galiwango RM, Musoke R, Lubayi J, Soekubuugo R, Kalibabala S, Ssekweyama V, et al. Evaluation of current rapid HIV test algorithms in Rakai, Uganda. J Virol Methods. 2013;192:25–27.